NO960866D0 - Fremgangsmåte til behandling av leversykdom og lignende indikasjoner med vasodilaterende midler - Google Patents

Fremgangsmåte til behandling av leversykdom og lignende indikasjoner med vasodilaterende midler

Info

Publication number
NO960866D0
NO960866D0 NO960866A NO960866A NO960866D0 NO 960866 D0 NO960866 D0 NO 960866D0 NO 960866 A NO960866 A NO 960866A NO 960866 A NO960866 A NO 960866A NO 960866 D0 NO960866 D0 NO 960866D0
Authority
NO
Norway
Prior art keywords
liver disease
treating liver
vasodilating agents
similar indications
indications
Prior art date
Application number
NO960866A
Other languages
English (en)
Norwegian (no)
Other versions
NO960866L (no
Inventor
William Alexander Mclean
Original Assignee
William Alexander Mclean
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by William Alexander Mclean filed Critical William Alexander Mclean
Publication of NO960866D0 publication Critical patent/NO960866D0/no
Publication of NO960866L publication Critical patent/NO960866L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
  • Medicines Containing Plant Substances (AREA)
NO960866A 1993-09-08 1996-03-04 Fremgangsmåte til behandling av leversykdom og lignende indikasjoner med vasodilaterende midler NO960866L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPM110493 1993-09-08
PCT/AU1994/000525 WO1995007080A1 (en) 1993-09-08 1994-09-05 A method of treating liver disease and like indications with vasodilating agents

Publications (2)

Publication Number Publication Date
NO960866D0 true NO960866D0 (no) 1996-03-04
NO960866L NO960866L (no) 1996-03-04

Family

ID=3777184

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960866A NO960866L (no) 1993-09-08 1996-03-04 Fremgangsmåte til behandling av leversykdom og lignende indikasjoner med vasodilaterende midler

Country Status (14)

Country Link
EP (1) EP0717625B1 (de)
JP (1) JP3842815B2 (de)
KR (1) KR100350156B1 (de)
CN (1) CN1115151C (de)
AT (1) ATE218869T1 (de)
CA (1) CA2170289C (de)
DE (1) DE69430807T2 (de)
FI (1) FI961029A0 (de)
HK (1) HK1003422A1 (de)
IL (1) IL110888A (de)
NO (1) NO960866L (de)
NZ (1) NZ273242A (de)
SG (1) SG49645A1 (de)
WO (1) WO1995007080A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854233A (en) * 1993-09-08 1998-12-29 Pharmacy And Therapeutic Advisory Consultancy Ltd. Method of treating liver disease and like indications with vasodilating agents
US6174917B1 (en) 1993-09-08 2001-01-16 Pharmacy And Therapeutic Advisory Consultancy Ltd. Method of treating liver disease and like indications with vasodilating agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004008A1 (en) * 1990-09-07 1992-03-19 Universidad De Alicante Composition for treating ocular pain
ZA923474B (en) * 1991-05-20 1993-01-27 Marion Merrell Dow Inc Diltiazem formulation

Also Published As

Publication number Publication date
NZ273242A (en) 2001-04-27
HK1003422A1 (en) 1998-10-30
ATE218869T1 (de) 2002-06-15
CN1130874A (zh) 1996-09-11
IL110888A0 (en) 1994-11-28
IL110888A (en) 1999-07-14
CA2170289A1 (en) 1995-03-16
FI961029A (fi) 1996-03-06
JPH09502188A (ja) 1997-03-04
EP0717625A1 (de) 1996-06-26
DE69430807T2 (de) 2002-12-19
CN1115151C (zh) 2003-07-23
CA2170289C (en) 2001-05-08
SG49645A1 (en) 1999-10-19
WO1995007080A1 (en) 1995-03-16
FI961029A0 (fi) 1996-03-06
NO960866L (no) 1996-03-04
DE69430807D1 (de) 2002-07-18
EP0717625A4 (de) 1997-12-29
JP3842815B2 (ja) 2006-11-08
EP0717625B1 (de) 2002-06-12
KR100350156B1 (ko) 2003-02-14

Similar Documents

Publication Publication Date Title
FI19991893A (fi) Säädellysti budesonidia vapauttava oraalisesti annettava koostumus ja budesonidin käyttö
DK0731699T3 (da) Fremgangsmåde til reduktion af legemsfedt i dyr ved indgivelse af konjugeret linolsyre
NO20074774L (no) Blandinger omfattende DNA-odeleggende midler og P53
IT8522574A0 (it) Composizione farmaceutica eprocedimento per trattare il corpo umano con essa.
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
EE9900428A (et) Köhavastased ravimkoostised
DK0661987T3 (da) Morphogeninduceret leverregeneration
NO894222L (no) Fremgangsmaater for behandling og profylakse av pneumocytis carinii pneumoni og andre sykdommer og forbindelser og formuleringer for anvendelse i nevnte metoder.
ATE201598T1 (de) Verwendung von moxonidin zur behandlung neuropathischer schmerzen
NO960866D0 (no) Fremgangsmåte til behandling av leversykdom og lignende indikasjoner med vasodilaterende midler
AR003979A1 (es) Administracion transdermica de vorozol.
GR3032224T3 (en) Therapeutic agent for threatened abortion.
CY1106702T1 (el) Χρηση ενος συνδυασμου μιας πουρινης και ενος παραγοντα δοτη μονοξειδιου του αζωτου για την προληψη ή την αγωγη γενετησιων δυσλειτουργιων
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE181669T1 (de) Verwendung von remacemid zur behandlung des morbus parkinson
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
ECSP951424A (es) Procedimiento para la administracion de azitromicina

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application